Chris Loughnane, is an engineer at Farm
Chris Loughnane, is an engineer at Farm

MEDdesign: Computer Vision In Early Stage Product Development

Much of the information gathered during evaluation in the early stages of product development is necessarily qualitative. Some quantifiable questions remain: how much deviation is there in the angle at which different doctors hold a laprascopic device? How does the movement of someone wearing a brace compare to that of a healthy person? Questions such as these can be answered using computer vision.

Continue reading

Tom Maeder, Senior Editor, MedTech Intelligence
Tom Maeder, Senior Editor, MedTech Intelligence

Making Translational Engineering Work: A Conversation with MIT’s Robert Langer

By Thomas Maeder
No Comments

For the past decade “translational science” and “translational medicine” have been cherished buzzwords, raising the prospect of faster, better, more seamless transfer of discoveries from bench to bedside. Too often, though, it doesn’t work. Differences in the cultures of academia and medical manufacturing, and a poor grasp of regulatory and reimbursement issues, or of what makes a bright idea into a clinically useful, commercially viable product have scuttled more than one promising innovation.

Continue reading

Lab-Developed Tests vs In Vitro Diagnostics – Balancing patient safety, access, innovation, and commerce

By Thomas Maeder
No Comments

On July 19 and 20, 2010, the Food and Drug Administration held a public meeting on regulatory oversight of laboratory-developed tests (LDTs). This is considered a major step in an ongoing debate on how best to handle two different, but often overlapping, sets of diagnostic tools in a manner that best serves patient safety and public health, while recognizing the realities of clinical practice and medical product development.

Stakeholder interest was intense. The original meeting space reached capacity and registration closed within two days, prompting FDA to shift the conference to a larger venue. Nearly 650 people attended, while 650 more watched via webcast.  FDA’s sense of urgency on the matter was further suggested by the June 10 issuance of “it has come to our attention” letters to six genetic testing companies, followed by another 14 on the opening day of the conference itself.

What are the issues? Why the concern? What does it all mean, and where might the Agency go?

Continue reading